Have a feature idea you'd love to see implemented? Let us know!

ORMP Oramed Pharmaceuticals Inc

Price (delayed)

$2.355

Market cap

$96.01M

P/E Ratio

4.62

Dividend/share

N/A

EPS

$0.51

Enterprise value

$11.74M

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and ...

Highlights
The EPS has surged by 200% year-on-year and by 96% since the previous quarter
The net income has soared by 100% QoQ
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Key stats

What are the main financial stats of ORMP
Market
Shares outstanding
40.77M
Market cap
$96.01M
Enterprise value
$11.74M
Valuations
Price to earnings (P/E)
4.62
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
1.16
EV/EBITDA
1.13
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
$10.14M
EBITDA
$10.36M
Free cash flow
-$1.55M
Per share
EPS
$0.51
Free cash flow per share
-$0.04
Book value per share
$4.36
Revenue per share
$0
TBVPS
$4.5
Balance sheet
Total assets
$184.22M
Total liabilities
$8.07M
Debt
$486,000
Equity
$177.07M
Working capital
$149.54M
Liquidity
Debt to equity
0
Current ratio
41.06
Quick ratio
40.92
Net debt/EBITDA
-8.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
9.9%
Return on equity
12.7%
Return on invested capital
5.7%
Return on capital employed
5.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ORMP stock price

How has the Oramed Pharmaceuticals stock price performed over time
Intraday
-1.05%
1 week
1.07%
1 month
-5.42%
1 year
8.03%
YTD
1.95%
QTD
-3.48%

Financial performance

How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.87M
Net income
$20.86M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The net income has soared by 100% QoQ
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The operating income has surged by 52% year-on-year and by 4.9% since the previous quarter

Growth

What is Oramed Pharmaceuticals's growth rate over time

Valuation

What is Oramed Pharmaceuticals stock price valuation
P/E
4.62
P/B
0.54
P/S
N/A
EV/EBIT
1.16
EV/EBITDA
1.13
EV/Sales
N/A
The EPS has surged by 200% year-on-year and by 96% since the previous quarter
The P/B is 75% less than the 5-year quarterly average of 2.2 and 8% less than the last 4 quarters average of 0.6
The equity has grown by 17% YoY and by 6% from the previous quarter
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Oramed Pharmaceuticals business performance
The ROE has soared by 195% YoY and by 92% from the previous quarter
The ROA has soared by 179% year-on-year and by 90% since the previous quarter
The company's return on invested capital has surged by 132% YoY and by 14% QoQ

Dividends

What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ORMP.

Financial health

How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's total liabilities has shrunk by 79% QoQ but it has increased by 43% YoY
Oramed Pharmaceuticals's quick ratio has shrunk by 71% YoY
ORMP's debt is 100% lower than its equity
Oramed Pharmaceuticals's debt to equity has shrunk by 100% QoQ
ORMP's debt has shrunk by 99% QoQ and by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.